Amira Nature Foods, AlarmCom, Flotek Moving In Tuesday's After Hours Session
Shares of Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) were trading up about 10 percent on Tuesday’s after-hours session, following the announcement of the company’s third quarter financial results. The small-cap biopharmaceutical company reported a net loss of ($0.11) per share on revenue of $9.1 million, ahead of the Street’s consensus estimate, which called for a net loss of ($0.14) per share on revenue of $7.95 million.
Also moving on its earnings report was Amdocs Limited (NASDAQ: DOX), which lost roughly 3.5 percent since the bell rang. The mid-cap tech company delivered fourth quarter earnings of $0.84 per share on revenue of $926.78 million. While earnings came in ahead of the Street’s consensus of $0.83 per share, revenues fell short of expectations for $934.69 million and guidance for $935 million.
Back to after-hours gainers, there’s Amira Nature Foods Ltd (NYSE: ANFI), which rose more than 17 percent since the market closed. The company announced an independent investigator found allegations against Amira Nature are unsubstantiated and unfounded.
The biggest decliner of the evening was Karyopharm Therapeutics Inc (NASDAQ: KPTI), down almost 8 percent since the bell rang. The decline seems to be a correction of the 8.85 percent surge seen during the day, probably responding to the company’s earnings call held on Monday.
Also of note shares of Flotek Industries Inc (NYSE: FTK) are down more than 5 percent after hours after falling by more than 37 percent on Tuesday. The company was the subject of reports questioning the accuracy of FracMax, a data analytics and visualization software application. The company issued an update to these claims, stating it will form an independent verification team to check the accuracy of the application. Results are expected in 2016.
Finally, AlarmCom Hldg Inc (NASDAQ: ALRM) was up more than 11 percent after beating net income and revenue expectations for its third quarter. Adjusted earnings came in at $0.14 per share, well above the Street’s consensus of $0.04 per share. Revenue of $54 million also beat expectations for sales of $47.62 million.
Disclosure: Javier Hasse holds no positions in any of the securities mentioned above.
© 2017 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.